249 related articles for article (PubMed ID: 8543941)
1. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride.
Rinne JO; Laihinen A; Ruottinen H; Ruotsalainen U; Någren K; Lehikoinen P; Oikonen V; Rinne UK
J Neurol Sci; 1995 Oct; 132(2):156-61. PubMed ID: 8543941
[TBL] [Abstract][Full Text] [Related]
2. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone.
Kaasinen V; Ruottinen HM; Någren K; Lehikoinen P; Oikonen V; Rinne JO
J Nucl Med; 2000 Jan; 41(1):65-70. PubMed ID: 10647606
[TBL] [Abstract][Full Text] [Related]
4. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
Antonini A; Schwarz J; Oertel WH; Pogarell O; Leenders KL
Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
[TBL] [Abstract][Full Text] [Related]
5. D2 receptor binding in dopa-responsive dystonia.
Künig G; Leenders KL; Antonini A; Vontobel P; Weindl A; Meinck HM
Ann Neurol; 1998 Nov; 44(5):758-62. PubMed ID: 9818931
[TBL] [Abstract][Full Text] [Related]
6. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
Tedroff J; Pedersen M; Aquilonius SM; Hartvig P; Jacobsson G; Långström B
Neurology; 1996 May; 46(5):1430-6. PubMed ID: 8628494
[TBL] [Abstract][Full Text] [Related]
7. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors.
Antonini A; Schwarz J; Oertel WH; Beer HF; Madeja UD; Leenders KL
Neurology; 1994 Jul; 44(7):1325-9. PubMed ID: 8035939
[TBL] [Abstract][Full Text] [Related]
8. Chronic exposure to dopamine agonists affects the integrity of striatal D
Politis M; Wilson H; Wu K; Brooks DJ; Piccini P
Neuroimage Clin; 2017; 16():455-460. PubMed ID: 28879087
[TBL] [Abstract][Full Text] [Related]
9. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
[TBL] [Abstract][Full Text] [Related]
10. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease.
Antonini A; Leenders KL; Vontobel P; Maguire RP; Missimer J; Psylla M; Günther I
Brain; 1997 Dec; 120 ( Pt 12)():2187-95. PubMed ID: 9448574
[TBL] [Abstract][Full Text] [Related]
11. Positron emission tomography study of human narcolepsy: no increase in striatal dopamine D2 receptors.
Rinne JO; Hublin C; Partinen M; Ruottinen H; Ruotsalainen U; Någren K; Lehikoinen P; Laihinen A
Neurology; 1995 Sep; 45(9):1735-8. PubMed ID: 7675236
[TBL] [Abstract][Full Text] [Related]
12. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride.
Farde L; Wiesel FA; Stone-Elander S; Halldin C; Nordström AL; Hall H; Sedvall G
Arch Gen Psychiatry; 1990 Mar; 47(3):213-9. PubMed ID: 1968328
[TBL] [Abstract][Full Text] [Related]
13. Effect of age on D2 dopamine receptors in normal human brain measured by positron emission tomography and 11C-raclopride.
Antonini A; Leenders KL; Reist H; Thomann R; Beer HF; Locher J
Arch Neurol; 1993 May; 50(5):474-80. PubMed ID: 8489403
[TBL] [Abstract][Full Text] [Related]
14. Chronic subthalamic nucleus stimulation and striatal D2 dopamine receptors in Parkinson's disease--A [(11)C]-raclopride PET study.
Thobois S; Fraix V; Savasta M; Costes N; Pollak P; Mertens P; Koudsie A; Le Bars D; Benabid AL; Broussolle E
J Neurol; 2003 Oct; 250(10):1219-23. PubMed ID: 14586606
[TBL] [Abstract][Full Text] [Related]
15. Dopamine D2 receptors in normal human brain: effect of age measured by positron emission tomography (PET) and [11C]-raclopride.
Antonini A; Leenders KL
Ann N Y Acad Sci; 1993 Sep; 695():81-5. PubMed ID: 8239318
[TBL] [Abstract][Full Text] [Related]
16. The decrease of dopamine D₂/D₃ receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB₁ cannabinoid receptors in Parkinson's disease: a preliminary autoradiographic study with the selective dopamine D₂/D₃ antagonist [³H]raclopride and the novel CB₁ inverse agonist [¹²⁵I]SD7015.
Farkas S; Nagy K; Jia Z; Harkany T; Palkovits M; Donohou SR; Pike VW; Halldin C; Máthé D; Csiba L; Gulyás B
Brain Res Bull; 2012 Apr; 87(6):504-10. PubMed ID: 22421165
[TBL] [Abstract][Full Text] [Related]
17. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease.
Antonini A; Leenders KL; Spiegel R; Meier D; Vontobel P; Weigell-Weber M; Sanchez-Pernaute R; de Yébenez JG; Boesiger P; Weindl A; Maguire RP
Brain; 1996 Dec; 119 ( Pt 6)():2085-95. PubMed ID: 9010012
[TBL] [Abstract][Full Text] [Related]
18. Decrease in human striatal dopamine D2 receptor density with age: a PET study with [11C]raclopride.
Rinne JO; Hietala J; Ruotsalainen U; Säkö E; Laihinen A; Någren K; Lehikoinen P; Oikonen V; Syvälahti E
J Cereb Blood Flow Metab; 1993 Mar; 13(2):310-4. PubMed ID: 8436624
[TBL] [Abstract][Full Text] [Related]
19. PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson's disease.
Rinne JO; Laihinen A; Rinne UK; Någren K; Bergman J; Ruotsalainen U
Mov Disord; 1993 Apr; 8(2):134-8. PubMed ID: 8474478
[TBL] [Abstract][Full Text] [Related]
20. A link between synaptic plasticity and reorganization of brain activity in Parkinson's disease.
Rebelo D; Oliveira F; Abrunhosa A; Januário C; Lemos J; Castelo-Branco M
Proc Natl Acad Sci U S A; 2021 Jan; 118(3):. PubMed ID: 33431672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
